Incyte Corporation has significantly scaled back its planned headquarters expansion in downtown Wilmington, marking a strategic shift in its physical infrastructure. The biotechnology firm sold two of its Bracebridge buildings to the Buccini/Pollin Group (BPG) as part of this downsizing effort. Current plans indicate that Incyte will occupy only about 15% of the space originally proposed for the downtown site. This decision follows a series of abandoned expansion plans and the cancellation of several research programs. Consequently, nearly $15 million in state incentives are now under scrutiny and review by Delaware officials. The move reflects a contraction in the company's growth ambitions and raises questions regarding its long-term operational strategy.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis